<DOC>
	<DOCNO>NCT02406248</DOCNO>
	<brief_summary>A multicenter , single arm , open label , Phase IV study evaluate safety describe cumulative incidence major cardiovascular event Ticagrelor Taiwanese patient non ST-segment ( segment eletrocardiogram present period ventricle depolarize ) elevation myocardial infarction</brief_summary>
	<brief_title>Brilinta Taiwan Post Approval Safety Study</brief_title>
	<detailed_description>This study conduct approximately 8 investigational centre Taiwan . It expect approximately 100 patient enrol study treatment . This study describe safety tolerability ticagrelor , assessment bleed event serious adverse event ( SAEs ) 1year follow Taiwanese non ST-elevation myocardial infarction ( NSTEMI ) patient .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Female male age least 20 year 3 . Patient consider ethnic Taiwanese 4 . Index event nonST elevation myocardial infarction 1 . Contraindication reason ticagrelor administer 2 . Index event acute complication Percutaneous coronary intervention ( PCI ) 3 . Patient plan urgent coronary artery bypass graft ( CABG ) within 7 day enrolment 4 . Oral anticoagulation therapy within 30 day prior enrolment stop 5 . Fibrinolytic therapy 24 hour prior enrolment , plan fibrinolytic treatment follow enrolment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NSTEMI</keyword>
</DOC>